Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Mansoor HusainStephen C BainOle K JeppesenIldiko LingvayRasmus SørrigMarianne B TreppendahlTina VilsbøllPublished in: Diabetes, obesity & metabolism (2020)
In SUSTAIN and PIONEER combined, glucagon-like peptide-1 analogue semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF.